Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multidose safety and tolerability study of liposomal amikacin for inhalation (Arikace) in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection
2006-006980-22Phase 2Completed
- Sponsor
- Insmed Incorporated
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of amikacin liposome inhalation suspension in cystic fibrosis (CF) and Pseudomonas aeruginosa pulmonary infection (2 cohorts), sponsored by Insmed Incorporated. Primary endpoints: Safety and tolerability over 28 days and Pharmacokinetics in serum and urine. Started Apr 2007; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa pulmonary infection
Beyond the preview
Go deeper on 2006-006980-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006980-22.